Announcements Trials
Browse Landscape

Phase

Phase 2 15Phase 3 3Phase 1/2 3Phase 1 2Phase 4 1

Status

Recruiting 3

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3Other hematologic neoplasm 1

Conditions

Burkitt Lymphoma 2Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1

Interventions

pembrolizumab 213Cyclophosphamide 123Nivolumab 110Carboplatin 94fludarabine 81Gemcitabine 78Specimen Handling 74Bevacizumab 73Injections 71venetoclax 70Magnetic Resonance Spectroscopy 67Dexamethasone 66Paclitaxel 64Biopsy 59atezolizumab 56Cisplatin 54Ipilimumab 50Temozolomide 46Lenalidomide 43Azacitidine 43Docetaxel 42Pemetrexed 41Rituximab 40Radiotherapy 40Oxaliplatin 40Fluorouracil 39Cetuximab 38durvalumab 37Cytarabine 36Capecitabine 36

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × Inotuzumab Ozogamicin × 1 year × Clear all
NCT06287229 2026-04-24

Phase Ib/II Study Assessing the Clinical Activity and Safety of Brexucabtagene Autoleucel as a Consolidation in Patients With Relapsed/Refractory (R/R) and Newly Diagnosed B-cell Acute Lymphocytic Leukemia (ALL) Post Cytoreduction With Mini-HCVD-inotuzumab-blinatumomab/HCVAD-inotuzumab-blinatumomab

M.D. Anderson Cancer Center

Phase 1/2 Recruiting
40 enrolled
Lymphoid

Burkitt Lymphoma, Recurrence

NCT01371630 2025-12-18

Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia

M.D. Anderson Cancer Center

Phase 1/2 Recruiting
276 enrolled
Lymphoid

Burkitt Lymphoma

NCT03104491 2025-06-05

Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia

Case Comprehensive Cancer Center

Phase 1/2 Recruiting
44 enrolled
LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡